Drug offers hope in treating ocular melanoma

Video

Richard Carvajal, MD, associate professor at Columbia University Medical Center, discusses one drug potential to treat ocular melanoma at ARVO 2018 in Honolulu.

The views expressed here belong to the author. They do not necessarily represent the views of Optometry Times or UBM Medica.

Richard Carvajal, MD, associate professor at Columbia University Medical Center, discusses one drug potential to treat ocular melanoma at ARVO 2018 in Honolulu.

Recent Videos
Sherrol Reynolds, OD, FAAO, values the ophthalmic-optometric collaboration on display at the summit, running from February 14-17, 2025 in San Juan, Puerto Rico.
Dr Carolyn Majcher chats about GA and posterior uveitis at AAOpt 2024
Dr. Mark Dunbar chats about his EyeCon 2024 presentation about diabetic eye care
Dr. Ferrucci summarizes his Vision Expo West presentations and shares clinical pearls for managing retinal cases.
Mohammad Rafieetary, OD, FAAO
Deborah Ferrington details a session on mitochondrial maintenance and retinal health in patients with AMD at ARVO 2024
Dr. John Sheppard discusses results from trials testing the efficacy of eye drops to treat dry eye disease
Related Content
FDA approved ranibizumab for diabetic macular edema - Image credit: Adobe Stock / ©BakiBullah

FDA approves ranibizumab for the treatment of diabetic macular edema via continuous delivery implant

Martin David Harp, Associate Editor, Ophthalmology Times
February 4th 2025
Article
Optometry Times You and Eye

You and Eye: What optometrists need to know about low vision

Miriam Korik, OD;Emily Kaiser Maharjan, Assistant Managing Editor
March 13th 2024
Podcast
Stephen Burns standing next to ophthalmoscope Image credit: ChrisMeyer/IndianaUniversity

Indiana University receives funding for advancing oculomics

Jordana Joy, Associate Editor
January 23rd 2025
Article
Advances in treatment for geographic atrophy

Advances in treatment for geographic atrophy

David S. Boyer, MD;Tina Mac Donald, OD, CDCES, FAAO;Leo P. Semes, OD, FAAO
October 11th 2023
Podcast
Ocugen announces 2-year safety and efficacy update for Phase 1_2 OCU400 for the treatment of RP - Image credit: Adobe Stock / ©Flashizzle_peopleimages.com

Ocugen announces 2-year safety and efficacy update for Phase 1/2 OCU400 for the treatment of RP

Sydney M Crago, Editor, Modern Retina
January 20th 2025
Article
Samsara Vision publishes positive imtermediate-term visual and safety outcomes of SING IMT - Image credit: Adobe Stock / ©Photocreo Bednarek

Positive intermediate-term visual and safety outcomes of SING IMT 6 months post-surgery announced by Samsara Vision

Martin David Harp, Associate Editor, Ophthalmology Times
January 20th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.